Usefulness of Platelet-to-Lymphocyte Ratio to Predict Long-Term All-Cause Mortality in Patients at High Risk of Coronary Artery Disease Who Underwent Coronary Angiography
Section snippets
Methods
The study population was identified from the Biomarkers of Atherosclerosis, Vascular and Endothelial Dysfunction in Heart Disease (BRAVEHEART) Study. The BRAVEHEART study is a prospective cohort study that consecutively recruited patients admitted to St Vincent's Hospital, Melbourne for coronary angiography and percutaneous coronary intervention (PCI) from October 2009 to May 2013, excluding patients with acute or chronic infections, systemic inflammatory conditions, recent or untreated
Results
A total of 514 patients were included in the study, of which 354 were male (69%) and 160 were female (31%), with mean ages of 63 ± 11 years and 65 ± 11 years, respectively. The mean follow-up period was 5.0 ± 1.3 years and there were 50 all-cause deaths. Table 1 lists the baseline clinical and biochemical characteristics of each of the 3 groups based on their preangiography PLR values (Tertile 1: PLR ≤ 106, Tertile 2: PLR 106.1 to 145, Tertile 3: PLR > 145). Patients in Tertile 3 were more
Discussion
In our study, we demonstrated that admission PLR was associated with long-term all-cause mortality in patients at high risk of CAD who underwent coronary angiography for various indications. Patients in the highest PLR tertile (Tertile 3) had a significantly higher rate of the primary end point compared with the lower 2 tertiles (Tertiles 1 and 2) and a similar trend was seen in the analysis based on the optimal cutoff at PLR of 137. In addition, we showed that PLR is a significant, independent
Disclosures
The authors have no conflicts of interest to disclose.
References (29)
- et al.
Inflammation in atherosclerosis: from pathophysiology to practice
J Am Coll Cardiol
(2009) - et al.
Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial)
Am J Cardiol
(2007) - et al.
Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris
Am J Cardiol
(2000) - et al.
The platelet-to-lymphocyte ratio as a predictor of all-cause mortality in patients with coronary artery disease undergoing elective percutaneous coronary intervention and stent implantation
J Saudi Heart Assoc
(2015) - et al.
Usefulness of the platelet-to-lymphocyte ratio in predicting angiographic reflow after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction
Am J Cardiol
(2014) - et al.
Association of platelet-to-lymphocyte ratio with severity and complexity of coronary artery disease in patients with acute coronary syndromes
Am J Cardiol
(2014) - et al.
Relation of platelet count to bleeding and vascular complications in patients undergoing coronary angiography
Am J Cardiol
(2010) - et al.
Usefulness of the lymphocyte concentration as a prognostic marker in coronary artery disease
Am J Cardiol
(1997) - et al.
Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention
Am J Cardiol
(2012) - et al.
Usefulness of the neutrophil-to-lymphocyte ratio to predict bare-metal stent restenosis
Am J Cardiol
(2012)
The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term adverse outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention
Atherosclerosis
Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention
Am J Cardiol
Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction
Am J Cardiol
Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention
Am J Cardiol
Cited by (0)
See page 1026 for disclosure information.
Andrew M. Wilson is supported by grants from the National Heart Foundation of Australia, the Diabetes Australia Research Trust, and the Australian Catholic University (Melbourne, Victoria, Australia). Arul Baradi is supported by an Australian Government Research Training Program Scholarship and an NHMRC Centre of Research Excellence in Cardiovascular Outcomes Improvement (CRE-COI) PhD Scholarship (Melbourne, Victoria, Australia).